Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice.
Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice.
复制标题
DOI：
10.1159/000507323
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Hamzavi I
中科院分区：
文献类型：
--
作者：
Orenstein LAV;Nguyen TV;Damiani G;Sayed C;Jemec GBE;Hamzavi I
化脓性汗腺炎（HS）是一种严重影响患者生活质量的慢性疼痛性皮肤病。虽然HS疗法的高质量试验仍然有限，但关于最佳治疗做法的医学知识正在迅速发展，导致最近出版了多项国际HS治疗指南。本综述比较了国际HS治疗指南，描述了常见和新兴HS疗法有效性的证据，并为将循证HS护理纳入实践提供了指导。尽管在国际HS指南中提到了50多种医疗和程序治疗，但在所有主要指南中，只有阿达木单抗和英夫利昔单抗被评为B级/弱推荐或更高级别。本综述描述了HS最常用的医学和程序治疗的适当患者选择和有效性。它还包括建议咨询，剂量和医疗治疗的持续时间，以及程序视频的执业皮肤科医生。目前，阿达木单抗以外的HS治疗很少得到高质量随机临床试验的支持，这导致了国际治疗指南的分歧。本文回顾了在普通皮肤科诊所实施HS治疗最佳实践的证据。
Hidradenitis suppurativa (HS) is a chronic painful skin disease that severely impairs patients’ quality of life. While high quality trials of HS therapies remain limited, medical knowledge of best treatment practices is rapidly evolving, leading to recent publication of multiple international treatment guidelines for HS. This review compares international HS treatment guidelines, describes evidence for effectiveness of common and emerging HS therapies, and provides guidance for integrating evidence-based HS care into practice. Although over 50 medical and procedural treatments are mentioned across international HS guidelines, only adalimumab and infliximab have grade B/weak recommendation or higher across all major guidelines. This review describes appropriate patient selection and effectiveness of the most commonly used medical and procedural treatments for HS. It also includes recommendations for counseling, dosing, and duration of medical therapies as well as procedure videos for the practicing dermatologist. Few HS treatments outside of adalimumab are currently supported by high quality randomized clinical trials, contributing to divergence in international treatment guidelines. This article reviews evidence for implementing best practices in HS treatment in the general dermatology clinic.
登录
查看更多内容
影响因子：
13.8
作者：
Alikhan, Ali;Sayed, Christopher;Alavi, Afsaneh;Alhusayen, Raed;Brassard, Alain;Burkhart, Craig;Crowell, Karen;Eisen, Daniel B.;Gottlieb, Alice B.;Hamzavi, Iltefat;Hazen, Paul G.;Jaleel, Tara;Kimball, Alexa B.;Kirby, Joslyn;Lowes, Michelle A.;Micheletti, Robert;Miller, Angela;Naik, Haley B.;Orgill, Dennis;Poulin, Yves
通讯作者：
Poulin, Yves
影响因子：
3.4
作者：
Alvarez, Pedro;Javier Garcia-Martinez, F.;Carlos Pascual, Jose
通讯作者：
Carlos Pascual, Jose
影响因子：
2.9
作者：
Anderson, Marianne D.;Zauli, Stefania;Jemec, Gregor B. E.
通讯作者：
Jemec, Gregor B. E.
影响因子：
3.2
作者：
Andino Navarrete, R.;Hasson Nisis, A.;Parra Cares, J.
通讯作者：
Parra Cares, J.
DOI：
10.1111/jdv.12952
发表时间：
2015-08-01
影响因子：
9.2
作者：
Blok, J. L.;Boersma, M.;Horvath, B.
通讯作者：
Horvath, B.